

FSFW-sponsored publications that are publicly available

Objective	Purpose	Organization	Link
D	ii	FSFW/Nielsen	COVID-19 State of Smoking Poll
D	ii	FSFW/Nielsen	Tobacco Use Patterns in Five Countries During the COVID-19 Lockdown Author: Derek Yach, DSc (Hon), MPH. Nicotine & Tobacco Research
D	ii	FSFW/Nielsen	Perceptions of Nicotine in Current and Former Tobacco & Tobacco Harm Reduction Product Users from Seven Countries SRNT 2020 poster
D	ii	FSFW/Nielsen	Perceptions of Relative Risk of E-cigarettes Over Time in Six countries SRNT poster
D	ii	FSFW/Nielsen	2019 Global Poll (Dashboard, Country Reports, Methods)
D	ii	FSFW/Nielsen	Tobacco smoking and nicotine delivery alternatives: patterns of product use and perceptions in 13 countries. Authors: Farhad Riahi, Sarah Rajkumar and Derek Yach. F1000Res. 2019;8:80
D	ii	FSFW/Nielsen	Perceptions of Nicotine in Current and Former Tobacco & Tobacco Harm Reduction Product Users from Seven Countries Author: Sarah Rajkumar (Accepted by Drugs and Alcohol Today, in press)
A, B	i , iii	Agenome	The First complete Zoroastrian-Parsi Mitochondria Reference Genome: Implications of mitochondrial signatures in an endogamous, non-smoking population Authors: Villoo Morawala-Patell, Naseer Pasha, Kashyap Krishnasamy, Bharti Mittal, Chellappa Gopala krishnan, Raja Mugasimangalam, Naveen Sharma, Arat i-Khanna Gupta, Perviz Bhothe Patell, Sudha Rao, Renuka Jain, and The Avestagenome Project®. bioRxiv

B, D	i, ii, iii,	CHRE UK	COVID-19: Risk of increase in smoking rates among England's 6 million smokers and relapse among England's 11 million ex-smokers. Author: Pooja Patwardhan. BJGP Open. 2020;4(2):bjgpopen20X101067.
B, D	i, ii, iii,	CHRE UK	'Quit During COVID-19'-staying smokefree in mental health in-patient settings. Authors: Pooja Patwardhan and Richard Driscoll. ecancermedicalscience. 2020;14:ed102. Published 2020 Jun 4.
B, D	i, ii, iii, vii	CHRE UK	Smoking Cessation and Mental Health Summit: Reclaiming the Stolen Years Healthcare Conferences UK
A, B, D	i, ii, iii	COREISS	Potential effects of using non-combustible tobacco and nicotine products during pregnancy: a systematic review. Authors: Marewa Glover and Carl V. Phillips Harm Reduction Journal. 2020;17(1):16. Published 2020 Mar 2.
A, B, D	i, ii, iii	COREISS/CHRE	Tobacco smoking in three “left behind” subgroups: indigenous, the rainbow community and people with mental health conditions. Authors: Marewa Glover, Pooja Patwardhan, and Kyro Selket. Drugs and Alcohol Today; Published July 2020
A, B	i, ii, iii	ECLAT/COEHAR	Smoking and SARS-CoV-2 Disease (COVID-19): Dangerous Liaisons or Confusing Relationships?. Authors: Giovanni Li Volti, Massimo Caruso and Riccardo Polosa. J Clin Med. 2020;9(5):1321. Published 2020 May 2.
A, B	i, ii, iii	ECLAT/COEHAR	COVID-19: counter-intuitive data on smoking prevalence and therapeutic implications for nicotine Authors: Riccardo Polosa and Grazia Caci. Intern Emerg Med. 2020;1-4. Published online ahead of print, 2020 May 19.

A, B	i, ii, iii	ECLAT/COEHAR	A Report on Smoking Detection and Quitting Technologies. Authors: Alessandro Ortis, Pasquale Caponnetto, Riccardo Polosa, Salvatore Urso and Sebastiano Battiato. Int J Environ Res Public Health. 2020;17(7):2614. Published 2020 Apr 10.
A, B	i, ii, iii	ECLAT/COEHAR	A double-edged sword: e-cigarettes, and other electronic nicotine delivery systems (ENDS): reply. Authors: Riccardo Polosa, Konstantinos Farsalinos and Domenico Prisco. Intern Emerg Med (2019).
A, B	i, ii, iii	ECLAT/COEHAR	Smoking and diabetes: dangerous liaisons and confusing relationships. Authors: Campagna D, Alamo A, Di Pino A, et al. Diabetology & Metabolic Syndrome 2019;11:85. Published 2019 Oct 24.
A, B	i, ii, iii	ECLAT/COEHAR	The effect of e-cigarette aerosol emissions on respiratory health: a narrative review. Authors: Riccardo Polosa, Renée O’Leary, Donald Tashkin, Rosalia Emma and Massimo Caruso. Expert Review of Respiratory Medicine 2019;13(9):899-915.
A, B	i, ii, iii, vii	ECLAT/COEHAR	Catania Conversation Centre of Excellence for the Acceleration of Harm Reduction (CoEHAR) project that brings together journalists, scientists and opinion leaders from all over the world to fill gaps in communication around THR.
C	I	EY Parthenon	Smoking Cessation Products and Services: Global Landscape Analysis
A, D	i, ii, vii	KAC	No Fire, No Smoke – the Global Sate of Tobacco Harm Reduction 2018
A, D	i, ii, vii	KAC	Tobacco harm reduction and the right to health 2020

B	i, ii, iii	Metaform	<p>Tobacco Harm Reduction: Underpinning Issues, Challenges, and Scope for Innovation.</p> <p>Authors: Samir Vinchurka, Nilesh Jain, Reena Jhamtani and Shilpa Gupta. International Journal of Health Research and Innovation, Vol. 8, No. 1, 2020 July 21</p>
A	i iii	Rose Research	<ul style="list-style-type: none"> • Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment (HAVE) • Assisting Smokers to Switch to a E-cigarette by Devaluing Combustible Cigarettes (RECON) • Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction • Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes
A	i, ii	Signals Analytics	<p>Using Advanced Analytics for the Early Detection of Pandemics and Outbreaks</p>
D	i	Yale	<p>An overview of tobacco control interventions in the Global South</p> <p>Authors: Navin Kumar, Kamila Janmohamed, Jeannette Jiang, Jessica Ainooson, Ameera Billings, Grace Chen, Faith Chumo, Lauren Cueto and Amy Zhang. Drugs and Alcohol Today, Vol. ahead-of-print. Published online 2020, May 25.</p>
D	i	Yale	<p>The scope of tobacco cessation randomized controlled trials in low- to middle-income countries: protocol for a scoping review.</p> <p>Authors: Navin Kumar, Jessica Ainooson, Ameera Billings, et al. Systematic Reviews 9, 86 (2020).</p>
D		FSFW	<p>Restricting Flavors in ENDS Could Have Repercussions Beyond Youths' Use.</p> <p>Authors: Brian E. Erkkila BE, Patricia Kovacevic and Derek Yach. Am J Public Health. 2020;110(6):777-778</p>

D		FSFW	Foundation for a Smoke-Free World: independent and making progress. Author: Derek Yach Lancet. 2019;394(10203):1008.
D		FSFW	Transformation of the Tobacco Industry. Author: Derek Yach Am J Public Health. 2019;109(7):e11.
D		FSFW	July 2020 India Country Report
D		FSFW	Smoking cessation programmes in China Author: Yuchen Xue. Lancet. 2020 Feb 15;395(10223):e28. doi: 10.1016/S0140-6736(19)32558-9. PMID: 32061299.

The following are publications in press, nearly final, or presentations that have not been disseminated

Objective	Purpose	Organization	Titles
A,D	i , iii	Biochromex	Nicotine Products Relative Risk Assessment
A, B, D	i, ii, iii	Cambridge Design	RRP Adoption Journey: Key Takeaways
A, B, D	i, ii, iii	Cambridge Design	RRP Adoption Journey Annex I: Summary of Findings
A, B, D	i, ii, iii	Cambridge Design	RRP Adoption Journey Annex II: Consumer Research
A, B, D	i, ii, iii	Cambridge Design	RRP Adoption Journey Annex III: Regulation and Public Healthcare
A, B, D	i, ii, iii	Cambridge Design	RRP Adoption Journey Annex IV: Solutions
A, B, D	i, ii, iii	Cambridge Design	RRP Adoption Journey Annex V: Product Technology
A, B, D	i, ii, iii	COREISS	Reducing Smoking-related Morbidity and Mortality in Kalaallit Nunaat (Greenland): A submission on the Naalakkersuisut Ministry of Health draft parliamentary Act on tobacco products and non-smoking environments (the Smoking Act).
A, B, D	i, ii, iii	COREISS	Suki and tobacco use among the iTaukei people of Fiji

A, B, D	i, ii, iii	COREISS	How New Zealand vapers might respond to e-liquid flavor bans, interest in vaping cannabinoids if legalized and current use of oral nicotine pouches. A survey of vape expo attendees. (SRNT 2020 poster)
A, B, D	i, ii, iii	COREISS	The rise of Wild-Wild-West style robberies of convenience stores for tobacco in New Zealand 2009-2018: Analysis of news reports. (SRNT 2020 poster)
D	i, iii, vii	EI/EY	Assessing the impact of smoking interventions on smoking prevalence: Lessons from five successful and five less successful countries on reducing smoking prevalence (draft Report)
D	i, iii, vii	EI/EY	Towards a smoker segmentation tool: Analysis of predictors for risk of harm, readiness to quit and optimal methods to quit smoking (draft Report)
A, C	i, ii	Signals Analytics	Regularly updated reports on early warning system and nicotine ecosystem

Deliverables expected from partners in next 12 months

Research Area	Expected Deliverables
Perceptions and opinions of tobacco harm reduction	<ul style="list-style-type: none"> • Report outlining perceptions of RRP in four LMICs • Report and publication outlining attitudes and perceptions of “last-mile” smokers and potential influencers • Multi-country study to examine smoking, RRP use, and perceptions of risk during COVID-19 lockdown • Launch of dashboard to use big data to monitor current scientific evidence and consumer perceptions of nicotine and nicotine products • Analysis of the impact of gender on perceptions of nicotine, RRP, and product use behavior in multiple countries

Assess the impact of smoke-free and reduced risk products on health outcomes	<ul style="list-style-type: none"> • Systematic review of toxin exposure across nicotine products • Clinical studies of biomarkers of exposure associated with different nicotine products • Development of novel research diagnostics to determine smoking and reduced risk product use • Differential epigenetic markers across nicotine products • Quantitative risk assessment and development of risk hierarchy across nicotine products • Guidelines and framework for the quality of tobacco harm reduction research, including assessing health outcomes, smoking prevalence, trends in product use • In vitro studies on comparative toxicity potential between cigarettes vs. RRP • Results of clinical trials of novel therapeutics and RRP for smoking cessation • Initiation of RCTs on promising cessation and switching protocols • Development of smartphone applications for use in clinical trials of cessation and RRP
Country Level Analysis of smoking cessation and reduced risk products	<ul style="list-style-type: none"> • Systematic, interdisciplinary evaluations of the drivers of smoking prevalence across multiple countries. Lessons learned about the impacts of factors such as taxation, regulatory environment, and public perception • Systematic review of tobacco harm reduction and cessation in the global south • Analyses of product use behavior India and evaluation of the relative risk of products on the Indian market
Subpopulation specific solutions for reducing smoking	<ul style="list-style-type: none"> • Reports on product use behavior and perceptions of tobacco harm reduction among indigenous people, pregnant women, and the LGBTQI community • Development of guidance for mental health care professionals to drive smoking cessation and switching to reduced risk products • Studies to assess the effectiveness of reduced risk products to reduce smoking prevalence among those with mental health disorders • Report on a smoker segmentation tool: analysis of predictors for risk of harm, readiness to quit and optimal methods to quit smoking